Department of Bioengineering, University of California, USA Introduction
*Corresponding author:Bill Tawil, Department of Bioengineering, UCLA School of Engineering, 420 Westwood Plaza, Room 5121, Engineering V. P.O. Box: 951600, Los Angeles, CA USA
Submission: November 11, 2024; Published: November 25, 2024
ISSN: 2578-0336Volume2 Issue1
Lipodystrophy results in the disorganization of adipose tissue which can result in the adipose tissue being lost in a specific region or throughout the body which can be due to multiple factors of genetics or medication. The market for Lipodystrophy itself looks promising and growth does seem apparent in order to find a cure, although it is classified as a rare disease. With many studies and publications suggesting potential that tissue engineering therapies may hold in being used to treat tissue engineering there is great promise. However, many past clinical trials and funding have provided inconclusive results for tissue engineering products and therapies in order to treat Lipodystrophy which indicates although there is promise for tissue engineering products. There is room for the field to develop and for more research to be conducted. The use of a product using a conventional tissue engineering approach of a scaffold, cells and growth factors with a type 1 collagen hydrogel with autologous-derived stem cells and VEGF may potentially prove to be useful in treating Lipodystrophy through the growth of adipose tissue. This review will look at the diseased and healthy tissue of Lipodystrophy, the market size and trends associated, the products available to treat this disease both existing and those currently in clinical trials as well as those in past clinical trials.
Keywords:Generalized; Acquired; Lipodystrophy; Adipose tissue; Biomaterials; Tissue engineering; Regenerative medicine
Abbreviations:BAT: Brown Adipose Tissue; CAGR: Compound Annual Growth Rate; CO2: Carbon Dioxide; FDA: Food and Drug Administration; FFA: Free Fatty Acids; HIV: Human Immunodeficiency Virus; IGF-1: Insulin-like Growth Factor 1; LEPR: Leptin Receptor; NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases; PBS: Phosphate Buffered Saline; PLG: Poly(lactide-co-glycolide); NaCl: Sodium Chloride; VEGF: Vascular Endothelial Growth Factor; WAT: White Adipose Tissue